HIV Drug Kaletra May Cause Adrenal Problems in Newborns: Study

French researchers indicate that use of the drug Kaletra to prevent transmission of HIV from mothers to newborns could cause some infants to suffer life-threatening adrenal problems. 

In a study published this week in the Journal of the American Medical Association, researchers indicate that Kaletra should no longer be used as a routine HIV neonatal prophylactic, because it is too dangerous to the newborn and there are other drugs on the market that could be used.

The study comes just a couple months after the FDA issued a warning about Kaletra toxicity in premature newborns.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

The researchers took blood samples from 50 newborns who were given Kaletra and compared them with 108 infants who were given other drugs to prevent HIV transmission. They found that seven of the children given Kaletra developed adrenal problems. There were no adrenal problems detected among newborns given other drugs.

Adrenal problems can cause development abnormalities in both boys and girls. Girls can develop a deep voice, excessive body hair, abnormal menstrual periods and genital defects. Boys with adrenal problems can develop exaggerated male traits like overdeveloped musculature, deep voice, enlarged penis but small testicles. Both sexes often grow up to be short as adults.

Kaletra (lopinavir/ritonavir) is an antiviral medication approved for the treatment of HIV infections in patients 14 days of age and older. It Is manufactured by Abbott Laboratories and was approved by the FDA in September 2000.

In March, the FDA issued a Kaletra drug safety communication, warning that premature babies could suffer serious heart, kidney or breathing problems if given the drug before their due date. A review of adverse events reported to the FDA revealed at least 10 cases of serious injuries that resulted from premature newborns being given Kaletra; one of which resulted in a child’s death due to cardiogenic shock.


"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Bard Argues Hernia Mesh Lawsuits Previously Selected for Bellwether Trials Are No Longer
Bard Argues Hernia Mesh Lawsuits Previously Selected for Bellwether Trials Are No Longer "Representative" (Posted today)

Bard claims two cases selected for the third and fourth bellwether trials are no longer representative of the litigation due to the plaintiffs' worsening injuries and need for additional surgeries due to their failed hernia mesh products.